In 2017, Biohaven was in need of clinical pharmacology and pharmacometrics expertise for Nurtec to supplement their drug development team. They engaged with Certara because of our proven experience in clinical pharmacology and pharmacometrics.

Certara was able to fill the gaps and worked closely alongside Biohaven’s scientists to use quantitative methods to advance Nurtec’s path to approval.

Certara Happy Family Sunset Biohaven 1

Certara’s contribution to the drug development program for Nurtec ODT was substantial. Their clinical pharmacology representative worked seamlessly with the Biohaven Development Team. Certara’s considerable expertise in clinical pharmacology and pharmacometrics and flawless execution supported Nurtec’s clinical development team and helped to prepare the clinical pharmacology NDA components.

Richard Bertz, PhD Vice President, Clinical Pharmacology & Pharmacometrics
Certara Migraine Biohaven 1

Migraine headaches are a debilitating neurological disorder that affects approximately 15% of the adult population in the United States (US), comprising approximately 38 million adults. Migraines rank as the third most prevalent disease worldwide and the seventh highest specific cause of disability worldwide.



沪公网安备 31010102007374 号

Powered by GlobalLink OneLink Software